• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oncology

Amgen completes $1.9B acquisition of Five Prime Therapeutics

April 16, 2021 By Sean Whooley

Amgen Five Prime Therapeutics

Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021. As of the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology, Pharmaceuticals Tagged With: Amgen, Five Prime Therapeutics

Oncopeptides seeks EU marketing authorization for multiple myeloma treatment

April 16, 2021 By Sean Whooley

Oncopeptides

Oncopeptides announced today that it submitted an application for European marketing authorization of its melflufen therapeutic. Conditional marketing authorization from the European Medicines Agency (EMA) is the aim for the company after its pivotal phase 2 Horizon study provided positive outcomes with melflufen (melphalan flufenamide) in treating relapsed refractory multiple myeloma, according to a news […]

Filed Under: Featured, Oncology, Pharmaceuticals Tagged With: Oncopeptides

OncoSec wins CE mark for electroporation device to treat solid tumors

April 14, 2021 By Sean Whooley

Oncosec

OncoSec Medical (NSDQ:ONCS) announced today that it received CE mark approval for its next-generation device to enable better uptake of anti-cancer therapies. GenPulse, part of OncoSec’s electroporation device platform for treating solid tumors, is designed to apply short electric impulses to a tumor, according to a news release. Get the full story at our sister site, […]

Filed Under: Oncology, Regulatory/Compliance Tagged With: OncoSec Medical

Terumo launches therapeutic interventional oncology team

April 13, 2021 By Sean Whooley

Terumo

Terumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021. Leuven, Belgium-based Terumo said in a news release that team’s introduction reflects its aspiration to be a global leader in the interventional oncology space by focusing on improving quality of life and survival. Team members work in […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Terumo Corp.

TriSalus, University of Texas to collaborate on solid tumor treatment study

April 8, 2021 By Sean Whooley

TriSalus-logo

TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors. The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology Tagged With: trisaluslifesciences, University of Texas MD Anderson Cancer Center

Pyxis Oncology closes $152M Series B

March 30, 2021 By Sean Whooley

Pyxis Logo

Biologics developer Pyxis Oncology announced today that it closed a Series B financing round worth $152 million. Cambridge, Mass.-based Pyxis had its financing round co-led by Arix Bioscience and RTW Investments. Existing investors including Leaps by Bayer, Longwood Fund, Agent Capital and Ipsen also contributed to the $152 million, which brings Pyxis’ total funding to […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Oncology, Pharmaceuticals Tagged With: Pyxis Oncology

Oncopeptides launches Pepaxto multiple meyeloma treatment

March 15, 2021 By Sean Whooley

Oncopeptides

Oncopeptides (STO:ONCO) announced today that it launched its Pepaxto drug for treating relapsed or refractory multiple myeloma. Boston-based Oncopeptides’ Pepaxto (melphalan flufenamide), which received accelerated FDA approval on Feb. 26, is now commercially available and the first patients are being treated with the drug, according to a news release. Pepaxto received approval in combination with […]

Filed Under: Business/Financial News, Featured, Oncology, Pharmaceuticals Tagged With: Oncopeptides

How Bionaut Labs aims to tackle brain tumors with microrobots

March 15, 2021 By Brian Buntz

Bionaut Labs

The roboticist Michael Shpigelmacher was one of the founders of PrimeSense, a robotic 3-D vision technology company Apple acquired in 2013. PrimeSense created technology empowering the Microsoft Xbox Kinect and the iPhone’s Face ID feature, allowing users to use facial recognition to unlock their phones.  Now Shpigelmacher has set his sights on drug-delivery with Bionaut […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Neurological, Oncology, Surgical, Technology Tagged With: 510(k), Bionaut Labs, glioma, Michael Shpigelmacher, Microsoft Kinect, neurology, oncology, PrimeSense

Bicara Therapeutics launches with $40M investment

March 15, 2021 By Sean Whooley

Bicara Therapeutics

Bicara Therapeutics announced today that it has launched with a $40 million investment from Biocon Limited. Cambridge, Mass.-based Bicara’s financing is earmarked for the advancement of its pipeline of first-in-class bifunctional antibodies developed between an engineering team in Bangalore, India, and the Cambridge-based executive team, according to a news release. Bicara’s pipeline includes tumor-targeted antibodies […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Bicara Therapeutics, biocon

AVEO to collaborate with Bristol Myers Squibb on renal cell carcinoma drugs

March 12, 2021 By Sean Whooley

AVEO Oncology Bristol Myers Squibb

AVEO Oncology (NSDQ:AVEO) announced today that it entered into a clinical trial collaboration with Bristol Myers Squibb. Boston-based AVEO’s collaboration and supply agreement with Bristol Myers Squibb is slated to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab), an anti-PD-1 therapy developed by Bristol Myers Squibb. The drugs will be evaluated in a pivotal Phase […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals Tagged With: AVEO Oncology, Bristol-Myers Squibb Co.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 29
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS